These findings indicate serial ctDNA monitoring could identify patients with muscle-invasive bladder cancer who benefit from adjuvant atezolizumab, while sparing patients who are persistently negative ...

Atezolizumab monotherapy improved overall survival for patients with advanced or metastatic non–small cell lung cancer (NSCLC) compared with single-agent chemotherapy, supporting the immunotherapy's ...

KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapies, today announced a clinical trial collaboration and supply ...

FDA has granted a Priority Review designation for the breakthrough programmed death ligand-1 inhibitor atezolizumab, for the treatment of bladder cancer. Following a review of the phase 2 results of ...

VIENNA -- Longer follow-up in the so-called IMpower010 trial further cements atezolizumab's (Tecentriq) value in treating stage II-IIIa non-small cell lung cancer (NSCLC) in patients with tumor cells ...

Please provide your email address to receive an email when new articles are posted on . A phase 3 trial designed to assess the addition of atezolizumab to chemotherapy as first-line treatment for ...

Sabari, MD, assistant professor at NYU Grossman School of Medicine in New York, discussed the phase 3 IMforte trial ...

The overall survival results were similar between the treatment arms for the overall cohort and for patients with PD-L1+ disease. Combination atezolizumab and bevacizumab did not improve overall ...

Atezolizumab plus bevacizumab, carboplatin and paclitaxel is recommended as an option for treating metastatic non-squamous non-small-cell lung cancer (NSCLC) in adults: who have not had treatment for ...